Literature DB >> 23249482

Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Ryka Moore1, Jennelle M Kyd, Rosemary Carzino, Davide Armstrong, Keith Grimwood, Diana C Otczyk, Allan W Cripps.   

Abstract

Pseudomonas aeruginosa is an important prognostic determinant in cystic fibrosis (CF). Little is known however, about P. aeruginosa induced local mucosal and systemic immune responses. Twenty CF children were categorized according to their P. aeruginosa status: (1) chronic lower respiratory tract infection (LRTI), (2) prior successfully treated initial LRTI, (3) isolated upper respiratory tract (URT) colonization, and (4) no known URT colonization or previous LRTI. Their antibody responses, and those of six non-CF disease controls, in serum and bronchoalveolar lavage (BAL) fluid to potential P. aeruginosa vaccine antigens outer membrane protein F (OprF), outer membrane protein H (OprH), catalase A (KatA) and a whole killed cell (WKC) extract were evaluated. Outer membrane protein G (OprG) responses were also measured in blood. Natural exposure, colonization and infection resulted in detectable antibody levels in BAL and serum in all CF groups. Both chronically infected and URT colonized CF children had substantially elevated immunoglobulin A antibody levels in the BAL fluid and sera toward the WKC extract and OprF antigen compared with the other groups of CF children and non-CF controls. The serum levels of specific P. aeruginosa antibodies involving immunoglobulin G and M isotypes increased with chronic LRTI, especially antibody levels to KatA, OprH and WKC extract, which were substantially greater in chronically infected children compared with all other groups. In conclusion, natural exposure, URT colonization and LRTI with P. aeruginosa all induce substantial mucosal and systemic antibody responses to potential vaccine antigens with chronically infected CF children having the highest levels.

Entities:  

Keywords:  KatA; OprF; OprG; OprH; Pseudomonas aeruginosa; cystic fibrosis; mucosal and systemic antibody; vaccine

Mesh:

Substances:

Year:  2012        PMID: 23249482      PMCID: PMC3891706          DOI: 10.4161/hv.23226

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  52 in total

1.  Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung.

Authors:  L D Thomas; M L Dunkley; R Moore; S Reynolds; D A Bastin; J M Kyd; A W Cripps
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

2.  Immunity to Pseudomonas aeruginosa induced by OprF following intestinal immunization.

Authors:  A W Cripps; M L Dunkley; D C Taylor; S Cousins; R L Clancy
Journal:  Adv Exp Med Biol       Date:  1995       Impact factor: 2.622

3.  Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis.

Authors:  D S Armstrong; K Grimwood; R Carzino; J B Carlin; A Olinsky; P D Phelan
Journal:  BMJ       Date:  1995-06-17

4.  Cystic fibrosis.

Authors:  M J Welsh; A E Smith
Journal:  Sci Am       Date:  1995-12       Impact factor: 2.142

Review 5.  The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis.

Authors:  A Buret; A W Cripps
Journal:  Am Rev Respir Dis       Date:  1993-09

6.  Use of subtractive hybridization to identify a diagnostic probe for a cystic fibrosis epidemic strain of Pseudomonas aeruginosa.

Authors:  Yasmin N Parsons; Stavroula Panagea; Catherine H M Smart; Martin J Walshaw; C Anthony Hart; Craig Winstanley
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

7.  Cloning and characterization of the katB gene of Pseudomonas aeruginosa encoding a hydrogen peroxide-inducible catalase: purification of KatB, cellular localization, and demonstration that it is essential for optimal resistance to hydrogen peroxide.

Authors:  S M Brown; M L Howell; M L Vasil; A J Anderson; D J Hassett
Journal:  J Bacteriol       Date:  1995-11       Impact factor: 3.490

8.  Immunisation with non-integral OMPs promotes pulmonary clearance of Pseudomonas aeruginosa.

Authors:  Linda D Thomas; Jennelle M Kyd; David A Bastin; Margaret L Dunkley; Allan W Cripps
Journal:  FEMS Immunol Med Microbiol       Date:  2003-07-15

9.  Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.

Authors:  A W Cripps; M L Dunkley; R L Clancy
Journal:  Infect Immun       Date:  1994-04       Impact factor: 3.441

10.  Immunoenzymometric assays for alkaline protease and exotoxin A from Pseudomonas aeruginosa: development and use in detecting exoproteins in clinical isolates from patients with cystic fibrosis.

Authors:  M C Jaffar-Bandjee; J Carrère; M Bally; O Guy-Crotte; C Galabert
Journal:  Eur J Clin Chem Clin Biochem       Date:  1994-12
View more
  4 in total

Review 1.  Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

2.  Evaluation of swabbing methods for estimating the prevalence of bacterial carriage in the upper respiratory tract: a cross sectional study.

Authors:  A L Coughtrie; R N Whittaker; N Begum; R Anderson; A Tuck; S N Faust; J M Jefferies; H M Yuen; P J Roderick; M A Mullee; M V Moore; S C Clarke
Journal:  BMJ Open       Date:  2014-10-30       Impact factor: 2.692

3.  Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous Pseudomonas aeruginosa Strains Based on Expression Profiling of Outer Membrane Proteins During Infection.

Authors:  Chang Liu; Xiaolei Pan; Bin Xia; Fei Chen; Yongxin Jin; Fang Bai; Gregory Priebe; Zhihui Cheng; Shouguang Jin; Weihui Wu
Journal:  Front Immunol       Date:  2018-07-26       Impact factor: 7.561

Review 4.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.